Lexicon Pharmaceuticals (LXRX) Capital Expenditures (2010 - 2024)

Lexicon Pharmaceuticals (LXRX) has 15 years of Capital Expenditures data on file, last reported at $474000.0 in Q4 2024.

• On a quarterly basis, Capital Expenditures changed N/A year-over-year to $474000.0 in Q4 2024; TTM through Dec 2025 was $781000.0, a 24.25% decrease from a year earlier, with the FY2024 full-year figure at $1.0 million, up 119.36% from the prior year.
• Capital Expenditures for Q4 2024 stood at $474000.0, up from $307000.0 in the prior quarter.
• Over the last five years, Capital Expenditures for LXRX reached as high as $1.2 million in Q4 2022 and fell as low as $4000.0 in Q3 2022.
• Historically, Capital Expenditures has averaged $275666.7 across 5 years, with a median of $139000.0 in 2023.
• On a YoY basis, Capital Expenditures climbed as much as 5317.39% in 2022 and fell as far as 98.12% in 2022.
• Year by year, Capital Expenditures stood at $54000.0 in 2020, then sank by 57.41% to $23000.0 in 2021, then jumped by 5317.39% to $1.2 million in 2022, then sank by 93.34% to $83000.0 in 2023, then jumped by 471.08% to $474000.0 in 2024.
• Per Business Quant data, the three most recent Capital Expenditures figures were $474000.0 in Q4 2024, $307000.0 in Q3 2024, and $250000.0 in Q2 2024.